2021
Targeted therapies for resectable lung adenocarcinoma: ADAURA opens for thoracic oncologic surgeons
Jones DR, Wu YL, Tsuboi M, Herbst RS. Targeted therapies for resectable lung adenocarcinoma: ADAURA opens for thoracic oncologic surgeons. Journal Of Thoracic And Cardiovascular Surgery 2021, 162: 288-292. PMID: 33691940, PMCID: PMC8519337, DOI: 10.1016/j.jtcvs.2021.02.008.Peer-Reviewed Original Research
2018
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis
Lee CK, Man J, Lord S, Cooper W, Links M, Gebski V, Herbst RS, Gralla RJ, Mok T, Yang JC. Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis. JAMA Oncology 2018, 4: 210-216. PMID: 29270615, PMCID: PMC5838598, DOI: 10.1001/jamaoncol.2017.4427.Peer-Reviewed Original ResearchConceptsNon-small cell lung carcinomaAdvanced non-small cell lung carcinomaSecond-line therapyCheckpoint inhibitorsOverall survivalCell lung carcinomaWild-type subgroupClinicopathological characteristicsHazard ratioClinical trialsLung carcinomaMutant subgroupSystematic reviewKRAS wild-type subgroupStandard second-line therapyKRAS mutant subgroupRelative treatment benefitOverall survival benefitCochrane Central RegisterType of chemotherapyProlonged overall survivalProlongs overall survivalEGFR-mutant tumorsPatients' clinicopathological characteristicsRandomized clinical trials
2016
Nivolumab and Pembrolizumab for Non–Small Cell Lung Cancer
Morgensztern D, Herbst RS. Nivolumab and Pembrolizumab for Non–Small Cell Lung Cancer. Clinical Cancer Research 2016, 22: 3713-3717. PMID: 27252413, DOI: 10.1158/1078-0432.ccr-15-2998.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungClinical Trials, Phase I as TopicHumansLung NeoplasmsNivolumabPrognosisProgrammed Cell Death 1 ReceptorRandomized Controlled Trials as TopicTreatment OutcomeConceptsCheckpoint inhibitorsClinical trialsAdvanced stage non-small lung cancerDeath-1 checkpoint inhibitorsLarge randomized clinical trialsNon-small lung cancerSecond-line docetaxelSurvivors 3 yearsBest supportive careSubset of patientsRandomized clinical trialsOverall survivalSupportive careCombination therapyLung cancerModest benefitPatientsPhase IImmunotherapyReliable predictorTherapyInhibitorsTrialsTreatmentNivolumab
2015
Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014
Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R. Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014. Journal Of Thoracic Oncology 2015, 10: s1-s63. PMID: 25535693, PMCID: PMC4346098, DOI: 10.1097/jto.0000000000000405.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Non-Small-Cell LungGenetic TherapyHumansImmunotherapyLung NeoplasmsMolecular Targeted TherapyRandomized Controlled Trials as Topic
2014
B7-H1/PD-1 Blockade Therapy in Non–Small Cell Lung Cancer
Gettinger S, Herbst RS. B7-H1/PD-1 Blockade Therapy in Non–Small Cell Lung Cancer. The Cancer Journal 2014, 20: 281-289. PMID: 25098289, DOI: 10.1097/ppo.0000000000000063.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsB7-H1 AntigenCarcinoma, Non-Small-Cell LungClinical Trials as TopicHumansImmunotherapyLung NeoplasmsProgrammed Cell Death 1 ReceptorRandomized Controlled Trials as TopicConceptsNon-small cell lung cancerAdvanced non-small cell lung cancerPhase III trialsCell lung cancerIII trialsPD-1Lung cancerClinical trialsPD-1/PD-L1 inhibitorsB7-H1/PDTumor PD-L1 expressionSevere autoimmune toxicityChemotherapy-naive patientsPD-L1 expressionPotential of immunotherapyPD-L1 inhibitorsDeath ligand 1Future clinical trialsNumber of antibodiesAutoimmune toxicityExpansion cohortBlockade therapyDurable responsesNSCLC patientsStandard therapy
2012
Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman SM, Hong WK, Herbst RS, Wistuba II, Heymach JV, Powis G. Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome. Journal Of The National Cancer Institute 2012, 104: 228-239. PMID: 22247021, PMCID: PMC3274509, DOI: 10.1093/jnci/djr523.Peer-Reviewed Original ResearchMeSH KeywordsAspartic AcidCarcinoma, Non-Small-Cell LungCell Line, TumorClinical Trials, Phase II as TopicCysteineDisease-Free SurvivalGene Expression ProfilingGene Expression Regulation, NeoplasticGenes, rasGenetic VectorsGlycineHumansImmunoblottingImmunoprecipitationKaplan-Meier EstimateLentivirusLung NeoplasmsMicroarray AnalysisMolecular Targeted TherapyMutationProto-Oncogene Proteins c-aktRandomized Controlled Trials as TopicSignal TransductionTOR Serine-Threonine KinasesTreatment OutcomeValineConceptsNon-small cell lung cancerKirsten rat sarcoma viral oncogene homologProgression-free survivalNSCLC cell linesWild-type KrasMutant KrasRefractory non-small cell lung cancerWorse progression-free survivalRat sarcoma viral oncogene homologRas2 Kirsten rat sarcoma viral oncogene homologSarcoma viral oncogene homologKaplan-Meier curvesCell lung cancerReverse-phase protein array studiesKRas proteinsHuman bronchial epithelial cellsCancer cell growthPatient tumor samplesCell linesImmortalized human bronchial epithelial cellsBronchial epithelial cellsProtein array studiesTumor gene expressionEvaluable patientsClinical outcomes
2009
Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non–Small Cell Lung Cancer
Hanrahan EO, Ryan AJ, Mann H, Kennedy SJ, Langmuir P, Natale RB, Herbst RS, Johnson BE, Heymach JV. Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non–Small Cell Lung Cancer. Clinical Cancer Research 2009, 15: 3600-3609. PMID: 19447868, DOI: 10.1158/1078-0432.ccr-08-2568.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarcinoma, Non-Small-Cell LungClinical Trials, Phase II as TopicEnzyme-Linked Immunosorbent AssayHumansKaplan-Meier EstimateLung NeoplasmsMeta-Analysis as TopicPiperidinesPredictive Value of TestsQuinazolinesRandomized Controlled Trials as TopicReceptors, Vascular Endothelial Growth FactorTreatment OutcomeVascular Endothelial Growth Factor AConceptsNon-small cell lung cancerProgression-free survivalCell lung cancerAdvanced non-small cell lung cancerVandetanib monotherapyLung cancerDisease progressionVEGF levelsVEGF valuesSimilar riskRandomized phase II studyVascular endothelial growth factor concentrationsExploratory retrospective analysisPhase II studyBaseline VEGF levelsPotential predictive markerLower VEGF levelsGrowth factor concentrationsBaseline VEGFCarboplatin-paclitaxelPFS advantageII studyPredictive markerRetrospective analysisHealthy subjectsPatient selection criteria and the FLEX Study
Herbst RS, Hirsch FR. Patient selection criteria and the FLEX Study. The Lancet 2009, 373: 1497-1498. PMID: 19410696, DOI: 10.1016/s0140-6736(09)60834-5.Peer-Reviewed Original ResearchAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarcinoma, Non-Small-Cell LungCetuximabClinical Trials, Phase III as TopicDisease-Free SurvivalErbB ReceptorsHumansLung NeoplasmsPatient SelectionRandomized Controlled Trials as TopicSurvival Rate
2008
Bevacizumab and Erlotinib: A Promising New Approach to the Treatment of Advanced NSCLC
Herbst RS, Sandler A. Bevacizumab and Erlotinib: A Promising New Approach to the Treatment of Advanced NSCLC. The Oncologist 2008, 13: 1166-1176. PMID: 18997180, DOI: 10.1634/theoncologist.2008-0108.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerF. Hoffmann-La Roche LtdEpidermal growth factor receptorAdvanced non-small cell lung cancerTumor growthRandomized phase II trialRecombinant humanized monoclonal antibodyHuman epidermal growth factor receptorCombination of bevacizumabPhase II trialSelective tyrosine kinase inhibitorAdditional clinical benefitSecond-line alternativeCell lung cancerPotential predictive markerHumanized monoclonal antibodyVascular endothelial growth factorTyrosine kinase inhibitorsSouth San FranciscoEndothelial growth factorGrowth factor receptorAdvanced diseaseErlotinib monotherapyII trialProspective trialBayesian adaptive design for targeted therapy development in lung cancer — a step toward personalized medicine
Xian Zhou, Suyu Liu, Kim ES, Herbst RS, Lee JJ. Bayesian adaptive design for targeted therapy development in lung cancer — a step toward personalized medicine. Clinical Trials 2008, 5: 181-193. PMID: 18559407, PMCID: PMC5481999, DOI: 10.1177/1740774508091815.Peer-Reviewed Original ResearchMeSH KeywordsBayes TheoremBiomarkers, TumorCarcinoma, Non-Small-Cell LungComputer SimulationEndpoint DeterminationHumansLung NeoplasmsRandomized Controlled Trials as TopicResearch DesignSample SizeConceptsDisease control rateBiomarker profilesControl rateTrial designRandomization ratesEffective agentLung cancerAdvanced stage non-small cell lung cancerStage non-small cell lung cancerNon-small cell lung cancerBaseline biopsy samplesPatient's biomarker profileCell lung cancerEarly stopping ruleEvaluable patientsPrimary endpointMore patientsPersonalized medicineAdaptive randomization designEffective treatmentBiomarker assessmentBiopsy samplesPatientsBayesian adaptive designIndividual tumors
2006
Angiogenesis inhibition in the treatment of lung cancer.
Vokes E, Herbst R, Sandler A. Angiogenesis inhibition in the treatment of lung cancer. Clinical Advances In Hematology And Oncology 2006, 4: 1-10; quiz 11-2. PMID: 17143257.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarboplatinCarcinoma, Non-Small-Cell LungClinical Trials, Phase III as TopicDisease-Free SurvivalErlotinib HydrochlorideHemorrhageHumansLung NeoplasmsNeovascularization, PathologicPaclitaxelProtein Kinase InhibitorsQuinazolinesRandomized Controlled Trials as TopicRisk FactorsSurvival RateVascular Endothelial Growth Factor AConceptsNon-small cell lung cancerVascular endothelial growth factorLung cancerAntiangiogenic therapyNon-squamous cell non-small cell lung cancerAnti-VEGF monoclonal antibody bevacizumabSmall molecule tyrosine kinase inhibitorsRandomized phase II studyRandomized phase III trialEpidermal growth factor receptor inhibitor erlotinibPhase II studyAddition of bevacizumabPhase III trialsSignificant survival benefitCell lung cancerSignificant clinical benefitMonoclonal antibody bevacizumabComprehensive treatment approachTyrosine kinase inhibitorsEndothelial growth factorImportant therapeutic targetOngoing studiesNSCLC settingBevacizumab treatmentII study
2005
Angiogenesis and lung cancer: prognostic and therapeutic implications.
Herbst RS, Onn A, Sandler A. Angiogenesis and lung cancer: prognostic and therapeutic implications. Journal Of Clinical Oncology 2005, 23: 3243-56. PMID: 15886312, DOI: 10.1200/jco.2005.18.853.Peer-Reviewed Original ResearchConceptsVascular endothelial growth factorAntiangiogenic agentsLung cancerSurrogate markerProangiogenic vascular endothelial growth factorMajority of patientsReliable surrogate markerTumor vascular developmentDownstream receptor signalingKey therapeutic strategyEndothelial growth factorVEGF receptor bindingMetastatic diseaseMost patientsCancer deathConventional chemotherapyCommon causeTherapeutic strategiesTherapeutic implicationsTumor typesTumor vasculatureTarget inhibitionAnticancer effectsCytostatic effectReceptor signaling
2003
Dose-comparative monotherapy trials of ZD1839 in previously treated non–small cell lung cancer patients
Herbst RS. Dose-comparative monotherapy trials of ZD1839 in previously treated non–small cell lung cancer patients. Seminars In Oncology 2003, 30: 30-38. PMID: 12644982, DOI: 10.1053/sonc.2003.50030.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsCarcinoma, Non-Small-Cell LungClinical Trials, Phase II as TopicEnzyme InhibitorsErbB ReceptorsGefitinibHumansLung NeoplasmsProtein-Tyrosine KinasesQuinazolinesRandomized Controlled Trials as TopicConceptsNon-small cell lung cancerAdvanced non-small cell lung cancerSymptom improvement rateTumor response rateDay groupSolid tumorsChemotherapy regimensIDEAL-2Ideal 1Lung cancerClinical trialsStage IIIResponse rateNon-small cell lung cancer patientsEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsAdvanced unresectable stage IIIMedian progression-free survivalObjective tumor response rateCell lung cancer patientsImprovement rateSelective epidermal growth factor receptor tyrosine kinase inhibitorReceptor tyrosine kinase inhibitorsPhase I clinical trialIressa Dose Evaluation
2002
ZD1839 (Iressa™) in Non-Small Cell Lung Cancer
Herbst RS, Kies MS. ZD1839 (Iressa™) in Non-Small Cell Lung Cancer. The Oncologist 2002, 7: 9-15. PMID: 12202783, DOI: 10.1634/theoncologist.7-suppl_4-9.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungErbB ReceptorsGefitinibHumansLung NeoplasmsProtein-Tyrosine KinasesQuinazolinesRandomized Controlled Trials as TopicConceptsNon-small cell lung cancerCell lung cancerEpidermal growth factor receptorLung cancerAdvanced non-small cell lung cancerEGFR tyrosine kinase inhibitor ZD1839Treatment of NSCLCCisplatin-based combination chemotherapyAnti-EGFR agentsConventional cytotoxic chemotherapyAvailable clinical dataGrowth factor receptorCombination chemotherapyCytotoxic chemotherapyPatient populationClinical dataClinical developmentGreater efficacyFactor receptorZD1839Less toxicityUseful targetChemotherapyCancerPrognosisEpidermal growth factor receptors as a target for cancer treatment: The emerging role of IMC-C225 in the treatment of lung and head and neck cancers
Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: The emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Seminars In Oncology 2002, 29: 27-36. PMID: 11894011, DOI: 10.1053/sonc.2002.31525.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Squamous CellCetuximabCombined Modality TherapyErbB ReceptorsGene Expression Regulation, NeoplasticHalf-LifeHead and Neck NeoplasmsHumansNeoplasm MetastasisNeoplasm Recurrence, LocalRadiation-Sensitizing AgentsRandomized Controlled Trials as TopicSalvage TherapyConceptsSquamous cell carcinomaEpidermal growth factor receptorIMC-C225Phase II trialGrowth factor receptorCell carcinomaII trialFactor receptorRadiation therapyNon-small cell lung cancer xenograftsNon-small cell lung cancerGemcitabine/carboplatin combinationSeparate phase II trialsAdvanced squamous cell carcinomaCell lung cancer xenograftsOngoing phase II trialEastern Cooperative Oncology GroupPhase III registration trialPhase I pharmacokinetic studyCultured human squamous cell carcinomasHuman squamous cell carcinomaPaclitaxel/carboplatinSecond-line settingStandard salvage regimensTreatment-naive patients